The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Cost Plus Fixed Fee definitive contract to Evolva Inc., a foreign-owned for-profit organization, for the development of NOOTKATONE, a Novel Toxicant and Repellent for Arthropod-Borne Virus Vectors (NTRAVV). The contract, which does not have a set-aside designation, has a potential value of $9,052,602.60 and a completion date of December 1, 2020. The place of performance is Lexington, Kentucky.
Generated 3/23/24, 1:33 PM